Egle Therapeutics
PrivateLast Round
Grant
Mar 2, 2026
Total Funding Raised
$61.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Egle Therapeutics is a biotechnology company that develops immunotherapies targeting regulatory T cells for the treatment of oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Egle Therapeutics Comparables
Compare Egle Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GentiBio | 84% | |
| Dualyx | 82% | |
| Quell Therapeutics | 81% | |
Egle Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 2, 2026 | ||||
| Grant | Mar 17, 2025 | ||||
| Series A | Oct 22, 2021 | ||||
| Convertible Debt | Jun 11, 2020 |
Egle Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A |
| Fund+ | Series A |
| Candriam | Series A |
| Bioqube Ventures | Series A |
| JDRF | Series A |
| Takeda Ventures | Convertible Debt, Series A |
| Bpifrance | Grant, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
$9M raised from Horizon Europe
- Jan 7, 2026
John Celebi appointed as the new chief executive officer.
Egle Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Egle Therapeutics's valuation, stock price, and market status.